therapeutics News and Research

RSS

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Scientists receive $10 million from HHMI for research on using viruses as therapeutic agents

Taking a bold step into a new era of biology, a team of scientists from the University of California San Diego, the J. Craig Venter Institute and Yale University has been awarded $10 million by the Howard Hughes Medical Institute to support research on using viruses as new therapeutic agents.

27 Jan 2023

Deep-learning model for zinc finger design allows reprogramming of human transcription factors

Researchers at the University of Toronto and New York University have developed a novel technology that can engineer proteins to target any stretch of DNA in the human genome, opening a door toward gene therapies for a broader range of health conditions.

27 Jan 2023

AI develops first-ever functional artificial protein

Scientists have developed an AI system that can produce artificial enzymes from scratch. Even though several of these enzymes’ artificially generated amino acid sequences differed noticeably from those of any known natural protein, they nonetheless performed as well in laboratory testing as those found in nature.

27 Jan 2023

Figuring out how cells safeguard their genomes during replication

Cells zealously protect the integrity of their genomes, because damage can lead to cancer or cell death. The genome, a cell’s complete set of DNA, is most vulnerable while it is being duplicated before a cell divides.

26 Jan 2023

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases.

From Ubiquigent Limited 23 Jan 2023

TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies

New company created to enable commercial manufacture of new cell and gene therapies.

From TTP plc 17 Jan 2023

New molecular profile of endometriosis to help improve therapeutic options

At Cedars-Sinai, a special and elaborate molecular profile of endometriosis has been engineered by investigators to help enhance therapeutic options for the millions of women suffering from the disease.

11 Jan 2023

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

...

From Orbit Discovery 5 Jan 2023

New technique provides an unlimited supply of patient-derived tissues to study AMD

Scientists used patient stem cells and 3D bioprinting to produce eye tissue that will advance understanding of the mechanisms of blinding diseases.

3 Jan 2023

Insight into the treatment for Crimean Congo Hemorrhagic Fever Virus

The Crimean Congo Hemorrhagic Fever Virus can be prevented by therapeutically relevant human monoclonal antibodies, according to research led by the University of California, Riverside.

30 Nov 2022

Novel approach increases the protein production efficiency of synthetic mRNAs

A group of synthetic biologists at the Hong Kong University of Science and Technology (HKUST) recently figured out a way to improve the efficiency of synthetic mRNA protein production by up to tenfold.

24 Nov 2022

Highlighting the potential of new techniques to study mental disorders

Researchers investigating the fundamental brain mechanics of autism spectrum disorder have discovered that a gene mutation known to be connected with the illness causes considerably more overstimulation of brain cells than in neuronal cells without the mutation.

23 Nov 2022

Expanding the CRISPR-based toolbox for extensive genome engineering

Researchers from North Carolina State University describe a variety of CRISPR-Cas systems-based molecular tools to rewrite, rather than just edit, significant portions of an organism’s DNA.

23 Nov 2022

Applying “programmable molecular scissors” to combat COVID-19 infection

As an approach that could be used to create a new class of antiviral drugs, synthetic biology was used by Cambridge scientists to artificially create enzymes programmed to attack the genetic code of SARS-CoV-2 and eliminate the virus.

17 Nov 2022

European project promotes top-notch research in biochemistry and biophysics

TWIN2PIPSA, a new European project funded with €1.2 million, will support leading research and intensive training in the biochemistry and biophysics of protein folding, with implications and applications in biomedicine and biotechnology.

15 Nov 2022

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022

microRNA molecules upregulate proteins instead of dampening it

microRNAs are thought to only suppress protein expression in dividing cells, such as tumor cells, and can contribute to the development of cancer.

11 Nov 2022

Regulating cholesterol production with novel protein

Everyone must have heard about cholesterol and how important it is to eat heart-healthy meals to keep it under control.

From The University of New South Wales (UNSW) 8 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

therapeutics News and Research

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Scientists receive $10 million from HHMI for research on using viruses as therapeutic agents

Deep-learning model for zinc finger design allows reprogramming of human transcription factors

AI develops first-ever functional artificial protein

Figuring out how cells safeguard their genomes during replication

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies

New molecular profile of endometriosis to help improve therapeutic options

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

New technique provides an unlimited supply of patient-derived tissues to study AMD

Insight into the treatment for Crimean Congo Hemorrhagic Fever Virus

Novel approach increases the protein production efficiency of synthetic mRNAs

Highlighting the potential of new techniques to study mental disorders

Expanding the CRISPR-based toolbox for extensive genome engineering

Applying “programmable molecular scissors” to combat COVID-19 infection

European project promotes top-notch research in biochemistry and biophysics

NIH funds research on mRNA vaccines to stop cancer development

microRNA molecules upregulate proteins instead of dampening it

Regulating cholesterol production with novel protein

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics